These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17537871)

  • 21. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
    Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
    Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
    Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
    Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
    Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
    Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
    Chu XY; Kato Y; Sugiyama Y
    Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
    Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
    Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
    Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
    Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
    Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
    Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
    Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
    Rivory LP; Bowles MR; Robert J; Pond SM
    Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.
    Sai K; Kaniwa N; Ozawa S; Sawada J
    Biomed Chromatogr; 2002 May; 16(3):209-18. PubMed ID: 11920947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
    Yokooji T; Kawabe Y; Mori N; Murakami T
    J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
    Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
    J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
    Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
    J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.